BACKGROUND

The Cancer Research UK Manchester Institute (http://www.cruk.manchester.ac.uk), an Institute of The University of Manchester (http://www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (http://www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are adjacent to The Christie NHS Foundation Trust (http://www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials.

The Institute has outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

We are situated in Manchester, England, a vibrant and dynamic city that is surrounded by beautiful countryside and has excellent transport links both nationally and internationally.

RESPONSIBILITIES

A 3 year postdoctoral position is available within Professor Caroline Dive's Clinical and Experimental Pharmacology Group to conduct cutting edge translational research on Small Cell Lung Cancer (SCLC). The focus of our research is translational medicine with an emphasis on next-generation sequencing in the characterisation of tumour heterogeneity, as well as prognostic or predictive biomarker discovery to aid novel therapeutics and clinical efficacy. The successful candidate will focus on unique lung cancer circulating tumour cell (CTC) derived explant tumour models (CDX) and analysis of CTCs isolated from lung cancer patients (see Hodgkinson et al., Nature Medicine, 2014). We have developed a library of CDX representing the full spectrum of chemosensitivity found in SCLC patients. These CDX have been used to generate an integrated oncogenomic datatset with the intent of developing novel platforms to investigate tumour response to both standard-of-care and novel targeted agents. This post, core funded by the CRUK Manchester Institute, sits within the CRUK Lung Cancer Centre of Excellence, a partnership between Manchester and University College London with associated opportunities for collaboration.

REQUIREMENTS

The successful applicant should have a PhD in computational biology, mathematics, computer science or a related discipline. A background in cancer biology is desirable but not required.

COMPENSATION

Salary in the range of GBP 30,000 - GBP 39,800 (dependent upon qualifications and experience)

TERMS

Duration of post: 3 years

HOW TO APPLY

To apply for this position please visit our website: http://www.cruk.manchester.ac.uk

For applicants who are unable to download this information from our website, please contact HR department on 0161 446 3231, email: jobs[at]cruk.manchester.ac.uk to have this information sent by post.

Job Ref: MI/15/80

Informal enquiries should be directed to Professor Caroline Dive, email: caroline.dive[at]cruk.manchester.ac.uk or her Preclinical Pharmacology Team lead Dr Kris Frese, email: kris.frese[at]cruk.manchester.ac.uk.

DEADLINE

Closing date: 18 December 2015.